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Inhibition of TOR signaling leads to extended longevity 
in both invertebrate and invertebrate species by 
modulating a number of downstream molecular 
pathways [1,2]. Drugs that inhibit the TOR pathway can 
serve as powerful tools to translate the effects of the 
TOR pathway on lifespan in simpler invertebrate model 
systems to more complex systems like mammals. One 
of the most promising drugs to slow aging is rapamycin, 
an inhibitor of TOR, which was previously shown to 
extend lifespan in mice when administered late in life 
[3]. As aging is one of the biggest risk factors for 
cancer, one of the outstanding questions is whether 
drugs that slow aging will also slow age-related 
increases in cancer incidence. A recent study describes 
how treatment of mice initiated early in life can not only 
retard aging but also slow age-related increase in 
cancer.  
 
Work by Anisimov and colleagues examines the impact 
on health and lifespan of Rapamycin treated inbred 
female mice from 2 months of age as compared to 
control littermates. However, its effects on aging if 
administered early and intermittently have not been 
known. Some of the effects include a significant decline 
in weight gain across the lifespan, a significant increase 
in regularity of estrous cycle before the onset of old age 
and more than 20% increase in survival rate along with 
increase of 10% in median lifespan. Rapamycin targets 
TOR, a Ser/Thr kinase, the kingpin of a conserved 
nutrient sensing pathway and causes decline in S6 
Kinase (S6K) phosphorylation at nano-molar 
concentrations (3). It has been earlier reported in an 
S6k1-/- mouse there is an increase in life span by 
activation of AMPK and increased resistance against 
many age related diseases but no effect on age-related 
increase in cancer incidence [4]. Hence, this study 
suggests that Rapamycin might have protective effects 
on age-related cancers through downstream effectors of 
TOR other than S6K. 
 
What are the possible mechanisms of decrease in age-
related cancer incidence in Rapamycin treated mice? As 
the Rapamycin treated mice not only had a decline in 
number of  tumor bearing mice  but also  showed  an  in- 
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crease in their median lifespan, it is possible that 
slowing aging prevents the accumulation of age-related 
cancers. The authors also report an increase in 
chromosomal aberrations in Rapamycin treated mice as 
compared to control littermates. Hence protection 
against DNA damage is unlikely to be the cause of the 
protective effects of Rapamycin, however it may 
enhance apoptosis. Earlier higher dose of Rapamycin 
has been shown to be effective in killing cancerous cells 
through its apoptotic effects [5,6]. Furthermore, a recent 
report shows a cancer cell specific apoptotic effect of 
high dose of Rapamycin is associated with complete 
dissociation of Raptor (regulatory associated protein of 
TOR) from mTORC1 along with decline in 
phosphorylation of eukaryotic binding protein-1 (4E-
BP1) and inhibition of eukaryotic initiation factor 4E 
(eIF4E) [7]. These observations indicate the possibility 
that Rapamycin increases lifespan and protection 
against cancer by decline in phosphorylation of S6K 
and 4E-BP1 respectively.  
 
One possible reason for the protective effects of 
Rapamycin on aging in mice may the reduced mortality 
from cancer. Anismov et al found a reduced mortality in 
mice suffering from tumors [8]. However, the sample 
size of mice not suffering from tumors was not large to 
examine whether Rapamycin extends lifespan 
independently of its effects on cancer. Nevertheless, the 
study argues that treatment with Rapamycin may help 
prevent the onset of age-related diseases like cancer and 
also aging. Furthermore, given slight change in food 
intake, no change in length of estrous cycle and an 
illegible change in water intake and body temperature 
among treated and control groups [8] argues that 
Rapamycin treatment does not lead to many side effects 
in this study. 
 
Cancer has been linked with aging since genetic 
mutations accumulate with age and delayed aging has 
been associated with lesser incidence of cancers [9]. 
Activation of TOR is involved in number of aging 
related diseases including cancer where mutations in 
upstream factors like PTEN, Ras and PI3K activate 
TOR signaling [10]. Not all TOR mimetic have been 
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[11], suggesting Rapamycin ingestion from early age 
inhibits aging that in turn provides protection against 
cancer. This study also provides an interesting insight 
for the possible use of Rapamycin in preventive 
medicine. Rapamycin could be given to people 
predisposed to cancer based on genetic and family 
history and may also be useful to treat cancer patients to 
prevent relapses and metastasis.  
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